BPC-157: Molecular Biology and Research Applications
BPC-157 (Body Protective Compound-157) is a synthetic pentadecapeptide consisting of 15 amino acids (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val) derived from a conserved sequence within the human gastric protein BPC. First characterized in the laboratory of Predrag Sikiric at the University of Zagreb, it has been used as a tool compound in in vitro research for several decades. Its primary research value lies in its stability in aqueous environments — the peptide resists proteolytic degradation under conditions that rapidly cleave most endogenous short-chain peptides — making it a reproducible reference compound for signaling pathway studies.
Chemical Structure
BPC-157 has a molecular weight of 1,419.55 Da and a CAS number of 137525-51-0. The sequence contains three consecutive proline residues (positions 3–5) that confer conformational rigidity and contribute to its protease resistance. It is produced as a lyophilized powder and reconstituted in sterile aqueous buffer for cell-based assays. Purity follows the ≥98% Verified Purity standard by reversed-phase HPLC and identity is verified by mass spectrometry.
Mechanism of Action
BPC-157 does not act through a single identified receptor. Research has identified several intracellular signaling interactions relevant to its use as a tool compound:
- VEGF signaling: BPC-157 has been reported to upregulate VEGF receptor expression and activate downstream PI3K/Akt signaling in endothelial cell models, supporting its use in angiogenesis pathway research.
- FAK/paxillin pathway: Studies in fibroblast cell lines have documented BPC-157-associated changes in focal adhesion kinase (FAK) and paxillin phosphorylation, relevant to cytoskeletal reorganization and cell migration modeling.
- NOS pathway: Research has examined BPC-157’s interactions with endothelial nitric oxide synthase (eNOS) in vascular cell models, with observed effects on NO production that inform vascular tone pathway studies.
These documented interactions make BPC-157 useful as a reference compound in studies examining growth factor receptor cross-talk, cytoskeletal dynamics, and extracellular matrix signaling.
Receptor Biology
BPC-157 does not have a confirmed endogenous receptor. Unlike conventional receptor agonists, its biological effects in cell models appear to involve modulation of multiple downstream signaling nodes rather than activation of a single defined receptor. This characteristic is relevant for experimental design — BPC-157’s effects may vary across cell lines expressing different baseline levels of FAK, VEGFR, or eNOS, and results should be interpreted accordingly.
Cell Signaling Pathways
The primary signaling pathways investigated in BPC-157 research include:
- PI3K/Akt/mTOR axis (downstream of VEGFR activation)
- FAK–Src–paxillin focal adhesion complex
- eNOS–NO–cGMP vascular pathway
- ERK1/2 MAPK cascade (observed in fibroblast migration models)
- Collagen prolyl hydroxylase activity (relevant to ECM assembly studies)
Current Research Applications
- Angiogenesis modeling: Endothelial tube formation assays and VEGF pathway activation studies
- Cell migration studies: Scratch assay and transwell migration models using fibroblast cell lines
- Focal adhesion signaling: FAK/paxillin phosphorylation time-course experiments
- Nitric oxide pathway research: eNOS activation and NO production quantification
- ECM remodeling: Collagen synthesis, crosslinking, and matrix metalloproteinase (MMP) activity studies
- Peptide stability reference: Used as a positive control in protease resistance assays due to its documented stability in physiological buffer conditions
Laboratory Applications
BPC-157 is supplied as a lyophilized powder (10 mg per vial) under the ≥98% Verified Purity standard. Reconstitution is typically performed in sterile water or phosphate-buffered saline. Working concentrations in published cell assay protocols vary; researchers should refer to their specific assay system requirements and conduct appropriate dose-response characterization. A Certificate of Analysis with HPLC chromatogram and mass spectrometry data is available per batch.
Handling and Storage
Lyophilized BPC-157 should be stored at −20°C and protected from light and moisture. Reconstituted solutions should be aliquoted and used promptly; freeze-thaw cycles degrade peptide integrity. The compound is stable under standard lyophilized storage conditions for the duration stated on the batch COA.
Research Considerations
- BPC-157 does not have an approved endogenous receptor target — experimental results require careful interpretation relative to the specific pathway being interrogated.
- Cell line selection is significant: VEGFR, FAK, and eNOS expression levels vary considerably across common laboratory cell lines.
- Concentration-response relationships should be established for each assay system; published in vitro concentrations span several orders of magnitude across different research models.
- All research is strictly in vitro. BPC-157 is not approved for any clinical, diagnostic, therapeutic, or veterinary use.
This content is provided for laboratory research purposes only and does not constitute medical, diagnostic, therapeutic, or veterinary guidance. All compounds are sold strictly for in vitro laboratory research use only.
